Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TREATMENT OF PLEURAL MESOTHELIOMA IN AN IMMUNOCOMPETENT RAT MODEL UTILIZING ADENOVIRAL TRANSFER OF THE HERPES-SIMPLEX VIRUS THYMIDINE KINASE GENE
Autore:
ELSHAMI AA; KUCHARCZUK JC; ZHANG HB; SMYTHE WR; HWANG HC; LITZKY LA; KAISER LR; ALBELDA SM;
Indirizzi:
HOSP UNIV PENN,THORAC ONCOL RES LAB,809 MALONEY BLDG,3600 SPRUCE ST PHILADELPHIA PA 19104 UNIV PENN,MED CTR,DEPT MED,DIV PULM CRIT CARE PHILADELPHIA PA 19104 UNIV PENN,MED CTR,DEPT SURG,THORAC SURG SECT PHILADELPHIA PA 19104 UNIV PENN,MED CTR,DEPT PATHOL,THORAC ONCOL RES LAB PHILADELPHIA PA 19104
Titolo Testata:
Human gene therapy
fascicolo: 2, volume: 7, anno: 1996,
pagine: 141 - 148
SICI:
1043-0342(1996)7:2<141:TOPMIA>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
MALIGNANT MESOTHELIOMA; BRAIN-TUMORS; VECTORS; CELLS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
26
Recensione:
Indirizzi per estratti:
Citazione:
A.A. Elshami et al., "TREATMENT OF PLEURAL MESOTHELIOMA IN AN IMMUNOCOMPETENT RAT MODEL UTILIZING ADENOVIRAL TRANSFER OF THE HERPES-SIMPLEX VIRUS THYMIDINE KINASE GENE", Human gene therapy, 7(2), 1996, pp. 141-148

Abstract

Previously, we have treated malignant mesothelioma (MM) growing in the peritoneal cavity of immunodeficient mice utilizing a recombinant adenovirus vector carrying the herpes simplex virus-thymidine kinase gene (Ad.RSVtk) followed by administration of the anti-viral drug ganciclovir (GCV). To mimic more closely the clinical situation in human MM, a syngeneic model of pleural MM was developed in immunocompetent Fischer rats. Administration of Ad.RSVtk into the pleural space of animals with established multifocal tumor followed by systemic GCV therapy resulted in significant tumor regression at 20 days in HSVtk/GCV-treated animals (average tumor weight 0.6 +/- 0.2 gram; n = 12) versus controlanimals (average weight 5.4 +/- 0.2 grams; n = 21; p < 0.001). In additional studies, Ad.RSVtk/GCV-treated animals had a mean survival of 34 days (average tumor weight 1.0 +/- 0.3 gram at death) versus 26 daysin control animals (average tumor weight 6.2 +/- 0.6 grams at death). A significant reduction in tumor burden was also seen when more advanced, bulkier disease was treated. These studies demonstrate the Ad.RSVtk/GCV system is effective in the treatment of pleural-based tumors inan immunocompetent host. However, there are limitations to this treatment approach that result in only small increments in survival.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/09/20 alle ore 06:45:23